Philip Ambery

12PUBLICATIONS
42CO-AUTHORS
Biologically active moleculesPharmacogenomicsPharmaceutical delivery technologiesFood properties (incl. characteristics and health benefits)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 30, 2026
Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system.

|Sep 30, 2025
An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon-like peptide-1 and glucagon receptor in healthy subjects.

James Goodman, Victoria E Parker, Carmel M McEniery

|May 21, 2025
Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.

Victor Wasehuus, J David Smeijer, Phil Ambery

|Oct 01, 2024
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.

J David Smeijer, Victor S Wasehuus, Neeraj Dhaun

|Jul 04, 2024
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials.

Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker

|Jun 05, 2024
Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?

Phil Ambery, Peter J Greasley, Robert I Menzies

Pageof 2

Frequent Collaborators

3 joint publications

Victoria Parker

3 joint publications

Hiddo J L Heerspink

3 joint publications

Anne-Kristina Mercier

3 joint publications

Magnus Åstrand